S&P 500   3,324.93 (+1.65%)
DOW   26,762.03 (+0.91%)
QQQ   278.15 (+2.40%)
AAPL   116.15 (+4.45%)
MSFT   206.74 (+2.00%)
FB   283.08 (+5.76%)
GOOGL   1,585.03 (+4.91%)
AMZN   3,238.71 (+2.40%)
TSLA   412.99 (+1.72%)
NVDA   526.17 (+4.18%)
BABA   314.06 (+1.99%)
CGC   18.80 (+2.51%)
GE   7.39 (-0.40%)
MU   50.76 (+1.52%)
AMD   78.85 (+3.21%)
T   26.92 (+1.58%)
F   7.97 (+3.51%)
ACB   4.02 (+4.96%)
GILD   58.87 (+0.26%)
NFLX   484.74 (-0.31%)
NIO   31.81 (+15.63%)
BA   148.59 (+0.30%)
DIS   121.52 (+2.57%)
S&P 500   3,324.93 (+1.65%)
DOW   26,762.03 (+0.91%)
QQQ   278.15 (+2.40%)
AAPL   116.15 (+4.45%)
MSFT   206.74 (+2.00%)
FB   283.08 (+5.76%)
GOOGL   1,585.03 (+4.91%)
AMZN   3,238.71 (+2.40%)
TSLA   412.99 (+1.72%)
NVDA   526.17 (+4.18%)
BABA   314.06 (+1.99%)
CGC   18.80 (+2.51%)
GE   7.39 (-0.40%)
MU   50.76 (+1.52%)
AMD   78.85 (+3.21%)
T   26.92 (+1.58%)
F   7.97 (+3.51%)
ACB   4.02 (+4.96%)
GILD   58.87 (+0.26%)
NFLX   484.74 (-0.31%)
NIO   31.81 (+15.63%)
BA   148.59 (+0.30%)
DIS   121.52 (+2.57%)
S&P 500   3,324.93 (+1.65%)
DOW   26,762.03 (+0.91%)
QQQ   278.15 (+2.40%)
AAPL   116.15 (+4.45%)
MSFT   206.74 (+2.00%)
FB   283.08 (+5.76%)
GOOGL   1,585.03 (+4.91%)
AMZN   3,238.71 (+2.40%)
TSLA   412.99 (+1.72%)
NVDA   526.17 (+4.18%)
BABA   314.06 (+1.99%)
CGC   18.80 (+2.51%)
GE   7.39 (-0.40%)
MU   50.76 (+1.52%)
AMD   78.85 (+3.21%)
T   26.92 (+1.58%)
F   7.97 (+3.51%)
ACB   4.02 (+4.96%)
GILD   58.87 (+0.26%)
NFLX   484.74 (-0.31%)
NIO   31.81 (+15.63%)
BA   148.59 (+0.30%)
DIS   121.52 (+2.57%)
S&P 500   3,324.93 (+1.65%)
DOW   26,762.03 (+0.91%)
QQQ   278.15 (+2.40%)
AAPL   116.15 (+4.45%)
MSFT   206.74 (+2.00%)
FB   283.08 (+5.76%)
GOOGL   1,585.03 (+4.91%)
AMZN   3,238.71 (+2.40%)
TSLA   412.99 (+1.72%)
NVDA   526.17 (+4.18%)
BABA   314.06 (+1.99%)
CGC   18.80 (+2.51%)
GE   7.39 (-0.40%)
MU   50.76 (+1.52%)
AMD   78.85 (+3.21%)
T   26.92 (+1.58%)
F   7.97 (+3.51%)
ACB   4.02 (+4.96%)
GILD   58.87 (+0.26%)
NFLX   484.74 (-0.31%)
NIO   31.81 (+15.63%)
BA   148.59 (+0.30%)
DIS   121.52 (+2.57%)
Log in
NASDAQ:TWST

Twist Bioscience Stock Forecast, Price & News

$79.26
-0.29 (-0.36 %)
(As of 10/29/2020 02:56 PM ET)
Add
Compare
Today's Range
$76.38
Now: $79.26
$80.28
50-Day Range
$61.72
MA: $78.15
$99.89
52-Week Range
$18.52
Now: $79.26
$100.30
Volume18,991 shs
Average Volume567,447 shs
Market Capitalization$3.54 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.42
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. Twist Bioscience Corporation has collaboration agreements with Pandion Therapeutics, Inc. and Schrödinger Inc. It also has a partnership with Serimmune Inc. to identify and evaluate SARS-CoV-2 therapeutic antibody candidates. The company was founded in 2013 and is headquartered in South San Francisco, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 1.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.09 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TWST
CUSIPN/A
CIKN/A
Phone800-719-0671
Employees414

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$54.38 million
Book Value$4.63 per share

Profitability

Net Income$-107,670,000.00
Net Margins-199.98%

Miscellaneous

Market Cap$3.54 billion
Next Earnings Date12/9/2020 (Estimated)
OptionableNot Optionable
$79.26
-0.29 (-0.36 %)
(As of 10/29/2020 02:56 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TWST News and Ratings via Email

Sign-up to receive the latest news and ratings for TWST and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Twist Bioscience (NASDAQ:TWST) Frequently Asked Questions

How has Twist Bioscience's stock been impacted by Coronavirus?

Twist Bioscience's stock was trading at $28.20 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TWST stock has increased by 181.6% and is now trading at $79.41.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Twist Bioscience?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Twist Bioscience
.

When is Twist Bioscience's next earnings date?

Twist Bioscience is scheduled to release its next quarterly earnings announcement on Wednesday, December 9th 2020.
View our earnings forecast for Twist Bioscience
.

How were Twist Bioscience's earnings last quarter?

Twist Bioscience Co. (NASDAQ:TWST) posted its quarterly earnings results on Thursday, August, 6th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.05. The business earned $21.20 million during the quarter, compared to the consensus estimate of $13.67 million. Twist Bioscience had a negative net margin of 199.98% and a negative return on equity of 57.24%. The firm's quarterly revenue was up 55.9% compared to the same quarter last year.
View Twist Bioscience's earnings history
.

What price target have analysts set for TWST?

3 brokers have issued 12-month price objectives for Twist Bioscience's shares. Their forecasts range from $42.00 to $42.00. On average, they anticipate Twist Bioscience's stock price to reach $42.00 in the next year. This suggests that the stock has a possible downside of 47.1%.
View analysts' price targets for Twist Bioscience
.

Who are some of Twist Bioscience's key competitors?

What other stocks do shareholders of Twist Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Twist Bioscience investors own include CrowdStrike (CRWD), Pfizer (PFE), Docusign (DOCU), Intel (INTC), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), JD.com (JD), Tesla (TSLA) and Twilio (TWLO).

Who are Twist Bioscience's key executives?

Twist Bioscience's management team includes the following people:
  • Dr. Emily Marine Leproust, Co-Founder, Chairman, Pres & CEO (Age 46, Pay $935.79k)
  • Mr. James M. Thorburn, Chief Financial Officer (Age 64, Pay $597.2k)
  • Dr. Patrick John Finn, Chief Commercial Officer (Age 48, Pay $558.68k)
  • Mr. Patrick Weiss, Chief Operating Officer (Age 49)
  • Mr. Mark Daniels Esq., Sr. VP, Chief Legal Officer, Chief Ethics & Compliance Officer and Sec. (Age 57)

When did Twist Bioscience IPO?

(TWST) raised $75 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Cowen served as the underwriters for the IPO and Allen & Company and Baird were co-managers.

What is Twist Bioscience's stock symbol?

Twist Bioscience trades on the NASDAQ under the ticker symbol "TWST."

Who are Twist Bioscience's major shareholders?

Twist Bioscience's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Emerald Advisers LLC (0.88%), Emerald Mutual Fund Advisers Trust (0.85%), State of Michigan Retirement System (0.12%), State of New Jersey Common Pension Fund D (0.07%), Conestoga Capital Advisors LLC (0.03%) and Ballentine Partners LLC (0.01%). Company insiders that own Twist Bioscience stock include Bill Peck, Emily M Leproust, James M Thorburn, Keith Crandell, Mark Daniels, Patrick John Finn, Patrick Weiss, Paula Green and William Banyai.
View institutional ownership trends for Twist Bioscience
.

Which institutional investors are selling Twist Bioscience stock?

TWST stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Conestoga Capital Advisors LLC, and State of New Jersey Common Pension Fund D. Company insiders that have sold Twist Bioscience company stock in the last year include Emily M Leproust, James M Thorburn, Mark Daniels, Patrick John Finn, Patrick Weiss, Paula Green, and William Banyai.
View insider buying and selling activity for Twist Bioscience
.

Which institutional investors are buying Twist Bioscience stock?

TWST stock was purchased by a variety of institutional investors in the last quarter, including State of Michigan Retirement System, Ballentine Partners LLC, Arthur M. Cohen & Associates LLC, Pacer Advisors Inc., Harel Insurance Investments & Financial Services Ltd., and Nisa Investment Advisors LLC.
View insider buying and selling activity for Twist Bioscience
.

How do I buy shares of Twist Bioscience?

Shares of TWST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Twist Bioscience's stock price today?

One share of TWST stock can currently be purchased for approximately $79.41.

How big of a company is Twist Bioscience?

Twist Bioscience has a market capitalization of $3.55 billion and generates $54.38 million in revenue each year. The company earns $-107,670,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis. Twist Bioscience employs 414 workers across the globe.

What is Twist Bioscience's official website?

The official website for Twist Bioscience is www.twistbioscience.com.

How can I contact Twist Bioscience?

Twist Bioscience's mailing address is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 800-719-0671 or via email at [email protected]

This page was last updated on 10/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.